During the past decade, Duke Clinical Research Institute conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 16 clinical trials were completed, i.e. on average, 45.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 9 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Duke Clinical Research Institute" #1 sponsor was "Duke University" with 10 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 7 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored, "Kyowa Hakko Kirin Pharma, Inc." with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Duke Clinical Research Institute" #1 collaborator was "Duke Clinical Research Institute" with 3 trials as a collaborator, "Agency for Healthcare Research and Quality (AHRQ)" with 2 trials as a collaborator, "Innovative Medicines Initiative" with 2 trials as a collaborator, "Janssen Research & Development, LLC" with 2 trials as a collaborator and "Kyowa Kirin Co., Ltd." with 2 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Duke Clinical Research Institute" are "Down Syndrome" (4 trials), "Healthy" (3 trials), "Heart Failure" (3 trials), "Hepatitis C" (3 trials) and "Myocardial Infarction" (3 trials). Many other conditions were trialed in "Duke Clinical Research Institute" in a lesser frequency.

Most popular intervention types in "Duke Clinical Research Institute" are "Drug" (45 trials), "Other" (14 trials), "Biological" (8 trials), "Behavioral" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "KRN23" (3 trials), "(MC-1) Pyridoxal 5'-phosphate" (1 trials), "AR09 solution" (1 trials) and "AZACTAM" (1 trials). Other intervention names were less common.

The vast majority of trials in "Duke Clinical Research Institute" are 65 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Duke Clinical Research Institute". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 51 completed trials in Duke Clinical Research Institute, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Duke Clinical Research Institute, 29 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 7 trials that are defined as “Not Applicable".